Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00601913 · ClinicalTrials.gov registry record · Early Phase 1
Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery
A Early Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
NCT00601913: Completed Early Phase 1 study, sponsored by Wake Forest University Health Sciences.
NCT00601913 is a Early Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 24 participants, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (55% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00601913, a Early Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment with erlotinib. PURPOSE: This clinical trial is studying how well erlotinib works when given before surgery in treating patients with head and neck cancer that can be removed by surgery.
Interventions
- OTHER laboratory biomarker analysis
- GENETIC protein analysis
- OTHER immunohistochemistry staining method
- GENETIC western blotting
- DRUG erlotinib hydrochloride
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2008-03 |
| Est. Completion | 2014-10 |
| Phase | Early Phase 1 |
What the finished NCT00601913 record still lists
NCT00601913 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 53-participant average among 2,764 other Early Phase 1 trials with a reported enrollment target (55% lower).
The record links to 0 conditions, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00601913 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00601913 about?
NCT00601913 is a clinical study titled "Erlotinib and Surgery in Treating Patients With Head and Neck Cancer That Can Be Removed by Surgery". RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment with erlotinib. PURPOSE: This clinic...
What is the current status of trial NCT00601913?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2008-03. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00601913?
The interventions under investigation include: laboratory biomarker analysis (OTHER), protein analysis (GENETIC), immunohistochemistry staining method (OTHER), western blotting (GENETIC), erlotinib hydrochloride (DRUG).
Who is sponsoring clinical trial NCT00601913?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00601913's enrollment target sits among peer trials
24 1037th of 2000 higher than 914 of 2,000 other Early Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Early Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia